Fax: (919) 681-5864
Risks, consequences, and new directions for its management
Version of Record online: 12 DEC 2003
Copyright © 2003 American Cancer Society
Volume 100, Issue 2, pages 228–237, 15 January 2004
How to Cite
Crawford, J., Dale, D. C. and Lyman, G. H. (2004), Chemotherapy-induced neutropenia. Cancer, 100: 228–237. doi: 10.1002/cncr.11882
- Issue online: 5 JAN 2004
- Version of Record online: 12 DEC 2003
- Manuscript Accepted: 2 OCT 2003
- Manuscript Revised: 1 OCT 2003
- Manuscript Received: 23 APR 2003
- Amgen Inc
- 2Filgrastim (r-metHuG-CSF) in the chemotherapy setting. In: MorstynG, DexterTM, FooteM, editors. Filgrastim (r-metHuG-CSF) in clinical practice. New York: Marcel Dekker, 1994: 103–106., .
- 3National Cancer Institute. Common toxicity criteria, version 2.0. Available from URL: http://ctep.cancer.gov/forms/CTCv20_4-30-992.pdf [access date January 3, 2003].
- 4Risk models for the prediction of chemotherapy-induced neutropenia (CIN) and its consequences: a systematic review and classification [abstract 5443]. Blood. 2001; 98: 413b., , , .
- 5Predictors for chemotherapy-related severe or febrile neutropenia: a review of the clinical literature. J Oncol Pharm Pract. 2002; 7: 141–147., , , .
- 6Clinical prediction models for febrile neutropenia (FN) and relative dose intensity (RDI) in patients receiving adjuvant breast cancer chemotherapy [abstract 1571]. Proc Am Soc Clin Oncol. 2001; 20: 394a., , , , , .
- 10Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control. 2002; 9: 203–211., , , et al.
- 19Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as an adjunct to chemotherapy in patients with high-risk Stage II or Stage III/IV breast cancer. J Clin Oncol. 2002; 20: 727–731., , , et al.
- 21Pegfilgrastim for the prevention of chemotherapy-induced neutropenic complications, with dosing once per chemotherapy cycle. Today's Therapeutic Trends. 2002; 20: 393–418..
- 25Chemotherapy-induced neutropenia and associated complications in randomized clinical trials: an evidence-based review [abstract 1638]. Proc Am Soc Clin Oncol. 2001; 20: 410a., , .
- 27First and all cycle febrile neutropenia hospitalizations (FNH) and costs in intermediate grade non-Hodgkins lymphoma (IGL) patients on standard-dose CHOP therapy [abstract 1810]. Blood. 2001; 98: 431a., , , .
- 28Incidence of febrile neutropenia (FN) is directly related to duration of severe neutropenia (DSN) after myelosuppressive chemotherapy [abstract 2840]. Proc Am Soc Clin Oncol. 2002; 21: 255b., , , , .
- 37Cost and mortality associated with febrile neutropenia in adult cancer patients [abstract 998]. Proc Am Soc Clin Oncol. 2002; 21: 250a., , , , .
- 38Factors associated with early termination of CHOP, and its association with overall survival among patients with intermediate-grade non-Hodgkin's lymphoma (NHL) [abstract 1539]. Proc Am Soc Clin Oncol. 2002; 21: 385a., , , , .
- 40An updated risk threshold model for G-CSF prophylaxis use in cancer chemotherapy: incorporation of patient out-of-pocket and indirect costs. Poster presented at the seventh annual meeting of the International Society for Pharmacoeconomics and Outcomes Research, Arlington, Virginia, May 19–22, 2002., , , .
- 44Incidence of low dose intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. In press., , .
- 50Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol. 2003; 21: 1431–1439. Erratum in: J Clin Oncol. 2003; 21: 2226., , , et al.
- 52Prospective patient registry for the development of risk models of neutropenic complications including febrile neutropenia (FN) [abstract 5593]. Blood. 2002; 100: 502b., , , , .
- 53Development and validation of the FACT-neutropenia [abstract 1791]. Blood. 2001; 98: 427a., , , .
- 54Decline in absolute neutrophil count (ANC) is associated with lower quality of life (QOL) in cancer patients receiving docetaxel [abstract 2808]. Proc Am Soc Clin Oncol. 2002; 21: 247b., , , et al.
- 55Quality of life (QOL) in patients with grade IV chemotherapy-induced neutropenia (CIN) [abstract 2920]. Proc Am Soc Clin Oncol. 2002; 21: 275b., , , et al.
- 56Febrile neutropenia is associated with an increase in the incidence, duration, and severity of chemotherapy toxicities [abstract 1812]. Blood. 2001; 98: 432a., , , , .
- 59A predictive model for neutropenia associated with cancer chemotherapy. Pharmacotherapy. 2000; 20( 7 pt 2): 104S–111S..
- 60Impact of outpatient treatment of febrile neutropenia (FN) on risk thresholds for G-CSF prophylaxis in cancer chemotherapy (CT) [abstract 1563]. Proc Am Soc Clin Oncol. 2001; 20: 392a., , , , .
- 63Predicting the risk of chemotherapy-induced neutropenia in patients with breast cancer: rationale for prospective risk model development. Poster presented at the 25th annual meeting of the San Antonio Breast Cancer Symposium, San Antonio, Texas, December 11–14, 2002., , , .